Centrexion Therapeutics Corporation Stock

CNTX

US15643W1009

Biotechnology & Medical Research

Latest news: Centrexion Therapeutics Corporation

24-01-07	Centrexion Therapeutics Corp. announced that it has received $3.255467 million in funding	CI
23-12-27	Centrexion Therapeutics Corp. announced a financing transaction	CI
23-11-26	Centrexion Therapeutics Corporation announced that it has received $2.3 million in funding	CI
23-11-13	Centrexion Therapeutics Corporation announced that it expects to receive $2.3 million in funding	CI
23-07-10	Centrexion Therapeutics Corp. announced that it has received $10.280238 million in funding	CI
23-06-13	Centrexion Therapeutics Corporation announced a financing transaction	CI
22-08-10	Centrexion Therapeutics Corporation announced that it has received $29.14 million in funding	CI
22-06-07	Centrexion Therapeutics Corporation announced that it has received $16.475 million in funding	CI
22-05-23	Centrexion Therapeutics Corporation announced that it expects to receive $16.475 million in funding	CI
22-05-11	Earnings Flash (CNTX) CONTEXT THERAPEUTICS Posts Q1 Loss $-0.22	MT
22-02-02	HC Wainwright Starts Context Therapeutics at Buy With $6 Price Target	MT
22-01-24	ThinkEquity Starts Context Therapeutics at Buy with $10 Price Target	MT
21-12-10	Wall Street Sees Upbeat Open, US CPI Rises More Than Expected	MT

More news

Analysts' recommendations: Centrexion Therapeutics Corporation

22-02-02	HC Wainwright Starts Context Therapeutics at Buy With $6 Price Target	MT
22-01-24	ThinkEquity Starts Context Therapeutics at Buy with $10 Price Target	MT

More recommendations

Press Releases: Centrexion Therapeutics Corporation

22-05-11	CONTEXT THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
22-04-11	Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022	GL
22-04-06	Context Therapeutics® to Participate in Two April 2022 Investor Conferences	GL
22-03-23	CONTEXT THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
22-03-23	Context Therapeutics® Reports Full Year 2021 Operating and Financial Results	AQ

More press releases

Managers and Directors: Centrexion Therapeutics Corporation

Manager	Title	Age	Since
James Campbell PSD	President	78	2013-01-31
Jeffrey Kindler CEO	Chief Executive Officer	70	2013-09-30
Randall M. Stevens CTO	Chief Tech/Sci/R&D Officer	-	2015-03-31

Director	Title	Age	Since
Sol Barer CHM	Chairman	78	2013-01-31
Jeffrey Kindler BRD	Director/Board Member	70	2013-09-30
Arnold Lewis Oronsky BRD	Director/Board Member	85	2013-01-31

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CENTREXION THERAPEUTICS CORPORATION	-.--%	-.--%	-	-	0
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+42.87%	+64.15%	63.77B
ARGENX SE	+0.35%	+3.20%	+14.40%	+81.76%	56.37B
LONZA GROUP AG	+0.53%	+1.96%	+16.24%	+103.35%	54.62B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+47.83%	44.06B
BEONE MEDICINES AG	-0.33%	-1.93%	+19.28%	+98.80%	42.11B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+225.14%	+866.21%	41B
GENMAB A/S	+3.27%	+47.96%	+112.84%	+96.58%	34.92B
CELLTRION, INC.	+1.22%	-1.44%	+14.57%	+46.95%	32.82B
INSMED INCORPORATED	+0.89%	+20.55%	-40.62%	+349.24%	24.7B
Average	+0.31%	+7.54%	+47.58%	+194.99%	43.82B
Weighted average by Cap.	+0.18%	+5.44%	+47.99%	+176.67%

See all sector performances

Centrexion Therapeutics Corp is a late clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to address the unmet medical need for the treatment of chronic pain. Its product candidate pipeline includes CNTX-4957, CNTX-0290, CNTX-6970, CNTX-2022 and CNTX-6016. Its product candidates are designed to treat pain conditions of multiple etiologies associated with a wide variety of common disease states. CNTX-4975 is designed to target and disrupt the signaling of pain-sensing nerve fibers. CNTX-0290 product candidate is an investigational small molecule SSTR4 agonist. CNTX-6970 is a potent and selective investigational CCR2 antagonist. CNTX-6970 is a small molecule intended to be administered orally. CNTX-2022 is a proprietary, high concentration topical gel formulation of lidocaine.

Employees

Sector

Biotechnology & Medical Research

More about the company